Added to YB: 2026-09-17
Pitch date: 2026-09-15
ACRS [neutral]
Aclaris Therapeutics, Inc.
Author Info
No bio for this author
Company Info
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.
Market Cap
$830.2M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.80
P/E
-9.62
EV/Sales
80.48
Sector
Pharmaceuticals
Category
growth
Biotech Conference Coverage: Week 2, Day 1 — Part 1: Aclaris Therapeutics, Inc.
ACRS (quick overview): Aclaris offers an immediate multi-shot immunology setup at $5.60: near-term Phase 1b ATI-052 data in atopic dermatitis and asthma could validate its IL-4R/TSLP bispecific strategy, followed roughly six weeks later by TSLP-monotherapy data. Management views a 40% FeNO reduction as encouraging and 50%+ as a “home run”; ATI-2138 could add underappreciated lichen-planus value and a potentially accelerated regulatory path.
Read full article (1 min)